Myovant Sciences
$21.929876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$21.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.25 (-1.11%) Today
-$0.35 (-1.57%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell MYOV and other stocks, options, and ETFs commission-free!
About MYOV
Myovant Sciences Ltd., also called Myovant Sciences, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. The listed name for MYOV is Myovant Sciences Ltd.
CEO
David C. Marek
Employees
214
Headquarters
London, Greater London
Founded
2016
Market Cap
2.04B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
977.30K
High Today
$22.75
Low Today
$21.93
Open Price
$22.20
Volume
559.43K
52 Week High
$30.90
52 Week Low
$5.98
Analyst Ratings
63%
of 8 ratings
Buy
63%
Hold
38%
Sell
0%
MYOV Earnings
-$0.95
-$0.63
-$0.32
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
-$0.85 per share
Actual
-$0.82 per share